Washington University School of Medicine recently received a two-year grant of $360,000 from JDRF to fund research testing the efficacy of the Biosense handheld breath ketone monitor in persons with type 1 diabetes during care with insulin and with the addition of a sodium glucose transporter inhibitor drug.
Biosense is a non-invasive option to capillary blood testing or urine testing for in-home biofeedback fat oxidation levels based on nutrition and exercise. It was launched in 2020 by Readout Health, a medical digital health startup.
Janet B. McGill, MD, MA, FACP will serve as the principal investigator, along with sub-investigators Maamoun Salam, MD and Alexis McKee, MD.
The clinical trial just received their first patient for the study. For more information on the clinical trial, visit Clinicaltrials.gov.
To read the official press release, visit PRNewswire.com.